Outset Medical, Inc. (NASDAQ:OM) Given Consensus Rating of “Hold” by Brokerages

Shares of Outset Medical, Inc. (NASDAQ:OM) have earned a consensus rating of “Hold” from the five analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $10.00.

A number of brokerages have recently commented on OM. Wall Street Zen cut shares of Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. TD Cowen reaffirmed a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. BTIG Research reduced their target price on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a report on Friday, March 27th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Legal & General Group Plc acquired a new position in shares of Outset Medical during the second quarter worth about $34,000. BNP Paribas Financial Markets increased its stake in shares of Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after acquiring an additional 2,034 shares during the period. Bank of New York Mellon Corp grew its position in Outset Medical by 4.1% during the first quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock worth $239,000 after buying an additional 2,435 shares during the period. Geode Capital Management LLC grew its position in Outset Medical by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 400,363 shares of the company’s stock worth $1,486,000 after buying an additional 3,104 shares during the period. Finally, Barclays PLC grew its position in Outset Medical by 9.8% during the fourth quarter. Barclays PLC now owns 37,682 shares of the company’s stock worth $140,000 after buying an additional 3,356 shares during the period.

Outset Medical Price Performance

Shares of NASDAQ:OM opened at $4.60 on Friday. The company has a 50-day simple moving average of $4.22 and a 200-day simple moving average of $4.17. Outset Medical has a one year low of $3.00 and a one year high of $21.98. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.97 and a current ratio of 6.29. The stock has a market capitalization of $85.28 million, a price-to-earnings ratio of -1.11 and a beta of 1.95.

Outset Medical (NASDAQ:OM) last announced its earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.04). Outset Medical had a negative net margin of 63.65% and a negative return on equity of 56.13%. The business had revenue of $27.86 million during the quarter, compared to analysts’ expectations of $28.90 million. On average, analysts predict that Outset Medical will post -3.82 EPS for the current year.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.